Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KZR NASDAQ:NBP NASDAQ:RNA NASDAQ:SLGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKZRKezar Life Sciences$7.29$7.16$3.53▼$7.55$53.86M0.4125,152 shs616,000 shsNBPI-Mab$1.85+2.8%$1.79$1.46▼$6.79$213.95M1.45849,462 shs249,686 shsRNAAvidity Biosciences$12.30+0.7%$12.83$11.40▼$16.77$210.40M0.93458,643 shs88,430 shsSLGLSol-Gel Technologies$77.21+2.4%$73.04$7.75▼$97.97$216.96M1.1234,271 shs31,115 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKZRKezar Life Sciences0.00%0.00%0.00%-1.22%+59.17%NBPI-Mab-3.23%-10.89%+20.81%-30.77%+179,999,900.00%RNAAvidity Biosciences0.00%-7.70%-1.21%-15.96%-63.60%SLGLSol-Gel Technologies+2.00%-3.89%+2.66%-5.53%+808.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKZRKezar Life Sciences$7.29$7.16$3.53▼$7.55$53.86M0.4125,152 shs616,000 shsNBPI-Mab$1.85+2.8%$1.79$1.46▼$6.79$213.95M1.45849,462 shs249,686 shsRNAAvidity Biosciences$12.30+0.7%$12.83$11.40▼$16.77$210.40M0.93458,643 shs88,430 shsSLGLSol-Gel Technologies$77.21+2.4%$73.04$7.75▼$97.97$216.96M1.1234,271 shs31,115 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKZRKezar Life Sciences0.00%0.00%0.00%-1.22%+59.17%NBPI-Mab-3.23%-10.89%+20.81%-30.77%+179,999,900.00%RNAAvidity Biosciences0.00%-7.70%-1.21%-15.96%-63.60%SLGLSol-Gel Technologies+2.00%-3.89%+2.66%-5.53%+808.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKZRKezar Life Sciences 1.67Reduce$6.00-17.70% DownsideNBPI-Mab 2.00Hold$9.00386.49% UpsideRNAAvidity Biosciences 2.28Hold$67.60449.59% UpsideSLGLSol-Gel Technologies 2.67Moderate Buy$197.50155.80% UpsideCurrent Analyst Ratings BreakdownLatest KZR, NBP, RNA, and SLGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026SLGLSol-Gel Technologies MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$285.006/19/2026RNAAvidity Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/18/2026RNAAvidity Biosciences Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.006/4/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D-)6/1/2026NBPI-Mab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026SLGLSol-Gel Technologies TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/22/2026RNAAvidity Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E-)5/22/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Sell (D+)5/18/2026NBPI-Mab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026RNAAvidity Biosciences Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/15/2026SLGLSol-Gel Technologies Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKZRKezar Life SciencesN/AN/AN/AN/A$9.57 per shareN/ANBPI-Mab$3.89M55.00N/AN/A$2.00 per share0.93RNAAvidity Biosciences$36.68M5.74N/AN/A$10.88 per share1.13SLGLSol-Gel Technologies$18.47M11.75N/AN/A$8.19 per share9.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKZRKezar Life Sciences-$56.03M-$6.17N/AN/AN/AN/A-55.42%-47.87%N/ANBPI-Mab-$46.27M-$0.36N/AN/AN/AN/AN/AN/AN/ARNAAvidity Biosciences-$322.30M-$0.97N/AN/AN/A-3,650.39%-44.92%-39.57%8/13/2026 (Estimated)SLGLSol-Gel Technologies-$6.13M-$0.34N/AN/AN/A-5.66%-3.17%-2.58%8/21/2026 (Estimated)Latest KZR, NBP, RNA, and SLGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/28/2026Q1 2026SLGLSol-Gel Technologies-$2.86-$1.31+$1.55$1.31$0.90 million$0.11 million5/14/2026Q1 2026RNAAvidity Biosciences-$1.05-$0.97+$0.08-$0.97$2.00 million$19.64 million5/11/2026Q1 2026KZRKezar Life Sciences-$0.98-$0.78+$0.20-$0.78$1.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKZRKezar Life SciencesN/AN/AN/AN/AN/ANBPI-MabN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKZRKezar Life SciencesN/A11.5211.52NBPI-MabN/A8.098.09RNAAvidity BiosciencesN/A9.2011.57SLGLSol-Gel TechnologiesN/A8.848.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKZRKezar Life Sciences67.90%NBPI-Mab38.38%RNAAvidity BiosciencesN/ASLGLSol-Gel Technologies26.18%Insider OwnershipCompanyInsider OwnershipKZRKezar Life Sciences10.40%NBPI-Mab22.10%RNAAvidity Biosciences3.83%SLGLSol-Gel Technologies66.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKZRKezar Life Sciences607.39 million6.70 millionNot OptionableNBPI-Mab380115.65 million90.09 millionN/ARNAAvidity Biosciences19017.11 million149.21 millionOptionableSLGLSol-Gel Technologies502.81 million941,000No DataKZR, NBP, RNA, and SLGL HeadlinesRecent News About These CompaniesOpaleye Management Inc. Buys 229 Shares of Sol-Gel Technologies (NASDAQ:SLGL) StockJuly 12 at 12:10 PM | americanbankingnews.comOpaleye Management Inc. Acquires 300 Shares of Sol-Gel Technologies (NASDAQ:SLGL) StockJuly 12 at 11:23 AM | americanbankingnews.comSol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Acquires 229 SharesJuly 11, 2026 | insidertrades.comOpaleye Management Inc. Acquires 229 Shares of Sol-Gel Technologies (NASDAQ:SLGL) StockJuly 10, 2026 | marketbeat.comInsider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires $22,107.00 in StockJuly 10, 2026 | marketbeat.comInsider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires $100,758.00 in StockJuly 5, 2026 | americanbankingnews.comSol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires $22,460.88 in StockJuly 3, 2026 | insidertrades.comSol-Gel Technologies (SLGL) Initiated with a Buy at Mizuho SecuritiesJune 26, 2026 | theglobeandmail.comSol-Gel Extends Patidegib IP to 2044 and Bolsters Cash Runway With $33.1 Million OfferingMay 30, 2026 | theglobeandmail.comSol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue EstimatesMay 28, 2026 | zacks.comSol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 28, 2026 | globenewswire.comInsider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires 1,500 Shares of StockMay 15, 2026 | insidertrades.comSol-Gel Technologies Ltd. Announces Pricing of $33.1 Million Underwritten Offering of Ordinary SharesMarch 23, 2026 | quiverquant.comQSol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten OfferingMarch 23, 2026 | globenewswire.comSol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue EstimatesMarch 19, 2026 | zacks.comSol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025March 19, 2026 | globenewswire.comThis Under-the-Radar Stock Has Surged 1,300% Over the Past YearMarch 13, 2026 | finance.yahoo.comSol-Gel Technologies (NASDAQ:SLGL) shareholders have earned a 940% return over the last yearFebruary 11, 2026 | finance.yahoo.comSol-Gel Technologies (SLGL) price target increased by 120.00% to 112.20February 4, 2026 | msn.comOpaleye Management Inc. Buys 1,151 Shares of Sol-Gel Technologies (NASDAQ:SLGL) StockJanuary 24, 2026 | insidertrades.comSol-Gel Technologies: Downgrading To 'Hold' As Success Relies On Upcoming Q4 CatalystJanuary 18, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWashington’s Quantum Push Puts IBM and IonQ on the ThroneBy Jeffrey Neal Johnson | June 25, 2026Cerebras Systems, Inc: The Next Rags-to-Riches AI Story?By Thomas Hughes | June 25, 2026Investors Are Buying Into Sweetgreen Again—Should They?By Jennifer Ryan Woods | June 22, 2026General Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsBy Thomas Hughes | July 2, 2026Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big MovesBy Leo Miller | June 17, 2026KZR, NBP, RNA, and SLGL Company DescriptionsKezar Life Sciences NASDAQ:KZRKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.I-Mab NASDAQ:NBP$1.85 +0.05 (+2.78%) Closing price 04:00 PM EasternExtended Trading$1.89 +0.04 (+2.00%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.Avidity Biosciences NASDAQ:RNA$12.30 +0.08 (+0.65%) As of 04:00 PM EasternAvidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Sol-Gel Technologies NASDAQ:SLGL$77.21 +1.82 (+2.41%) Closing price 04:00 PM EasternExtended Trading$76.70 -0.50 (-0.65%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings Why ASML’s AI Monopoly Is Still Getting Stronger Alphabet’s AI Spending Question Looms Over Q2 Earnings CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks 2 Quantum Stocks That Could Challenge IonQ’s Leadership 3 Small-Cap Stocks Trading Under $10 With Room to Run Plot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
